RTTNews | Apr 1, 2021 09:59AM EDT

09:59 Thursday, April 1, 2021 (RTTNews.com) - Emergent BioSolutions Inc. (EBS) shares are sliding as Johnson and Johnson (JNJ) identified that one batch of drug substance for its COVID-19 vaccine at Emergent failed to meet quality standards. In an email statement, JNJ claimed that the batch was never part of the manufacturing process.

Currently, Emergent shares are at $81.11, down 12.70 percent from the previous close of $92.91. For the 52-week period, the shares are at $53.35-$137-61 on average volume of 592,313.

Read the original article on RTTNews ( https://www.rttnews.com/3182149/emergent-biosolutions-down-after-j-j-revealed-production-issues-with-covid-vaccine.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved